RO7851624

RO7851624 (also known as RG6615) is an investigational trispecific T-cell engager (TCE) developed by Genentech (Roche) for the treatment of relapsed or refractory multiple myeloma (RRMM). The molecule is designed to simultaneously target two tumor-associated antigens—B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D)—on the surface of malignant plasma cells, while also binding to the CD3 epsilon subunit of the T-cell receptor complex. By engaging two distinct myeloma antigens, RO7851624 aims to enhance tumor cell recognition and mitigate the risk of immune escape through antigen loss or downregulation, a common resistance mechanism in single-target therapies. The drug is currently being evaluated in Phase Ia/b clinical trials, specifically focusing on patients who have been triple-class exposed to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies.

Other names

BCMA x GPRC5D x CD3 trispecific antibodyGPRC5D/BCMA/CD3 trispecific T-cell engager